Inactive Instrument

Lonza Group AG Share Price Swiss Exchange

Equities

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 16:20:00 11/06/2024 BST
495.3 CHF 0.00% Intraday chart for Lonza Group AG
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6.66B 7.42B 582B Sales 2025 * 7.63B 8.5B 667B Capitalization 35.7B 39.78B 3,123B
Net income 2024 * 893M 995M 78.1B Net income 2025 * 1.11B 1.23B 96.81B EV / Sales 2024 * 5.77 x
Net Debt 2024 * 2.72B 3.03B 237B Net Debt 2025 * 3.32B 3.7B 290B EV / Sales 2025 * 5.12 x
P/E ratio 2024 *
40.5 x
P/E ratio 2025 *
32.4 x
Employees -
Yield 2024 *
0.9%
Yield 2025 *
1.06%
Free-Float 96.79%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW